The CLL Landscape is Rapidly a'changing...
Sally Church (Pharma Strategy Blog)
Free comprehensive update on the CLL landscape from one of the top oncology commentators, including GILD's idelalisib, Roche's GA-101 (obinutuzumab), PCYC / JNJ (ibrutinib), and INFI (IPI-145), and ABBV (ABT-199).
New Updates to EMA Database Will Soon Make Summary Results of Clinical Trials Public
Alec Gaffney (Regulatory Focus / RAPS)
Rules for Biotech and Life Sciences Investing Part 2: Binary Events
David Sable
Blogging on Biotech: Reflections and a "Best of" List
Bruce Booth (LifeSciVC)
Bubble-icious Biotech
Nathan Sadeghi-Nejad
Drug Reps and Doctors: Madras clinic ousts salesmen and their samples
Markian Hawryluk(Bend Bulletin)
Sally Church (Pharma Strategy Blog)
Free comprehensive update on the CLL landscape from one of the top oncology commentators, including GILD's idelalisib, Roche's GA-101 (obinutuzumab), PCYC / JNJ (ibrutinib), and INFI (IPI-145), and ABBV (ABT-199).
New Updates to EMA Database Will Soon Make Summary Results of Clinical Trials Public
Alec Gaffney (Regulatory Focus / RAPS)
Rules for Biotech and Life Sciences Investing Part 2: Binary Events
David Sable
Blogging on Biotech: Reflections and a "Best of" List
Bruce Booth (LifeSciVC)
Bubble-icious Biotech
Nathan Sadeghi-Nejad
Drug Reps and Doctors: Madras clinic ousts salesmen and their samples
Markian Hawryluk(Bend Bulletin)
RSS Feed
